Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

医学 心肌梗塞 冲程(发动机) 内科学 人口 随机对照试验 血管疾病 阿司匹林 血小板聚集抑制剂 相对风险 心脏病学 外科 置信区间 机械工程 环境卫生 工程类
出处
期刊:PubMed [National Institutes of Health]
卷期号:308 (6921): 81-106 被引量:545
链接
标识
摘要

To determine the effects of "prolonged" antiplatelet therapy (that is, given for one month or more) on "vascular events" (non-fatal myocardial infarctions, non-fatal strokes, or vascular deaths) in various categories of patients.Overviews of 145 randomised trials of "prolonged" antiplatelet therapy versus control and 29 randomised comparisons between such antiplatelet regimens.Randomised trials that could have been available by March 1990.Trials of antiplatelet therapy versus control included about 70,000 "high risk" patients (that is, with some vascular disease or other condition implying an increased risk of occlusive vascular disease) and 30,000 "low risk" subjects from the general population. Direct comparisons of different antiplatelet regimens involved about 10,000 high risk patients.In each of four main high risk categories of patients antiplatelet therapy was definitely protective. The percentages of patients suffering a vascular event among those allocated antiplatelet therapy versus appropriately adjusted control percentages (and mean scheduled treatment durations and net absolute benefits) were: (a) among about 20,000 patients with acute myocardial infarction, 10% antiplatelet therapy v 14% control (one month benefit about 40 vascular events avoided per 1000 patients treated (2P < 0.00001)); (b) among about 20,000 patients with a past history of myocardial infarction, 13% antiplatelet therapy v 17% control (two year benefit about 40/1000 (2P < 0.00001)); (c) among about 10,000 patients with a past history of stroke or transient ischaemic attack, 18% antiplatelet therapy v 22% control (three year benefit about 40/1000 (2P < 0.00001)); (d) among about 20,000 patients with some other relevant medical history (unstable angina, stable angina, vascular surgery, angioplasty, atrial fibrillation, valvular disease, peripheral vascular disease, etc), 9% v 14% in 4000 patients with unstable angina (six month benefit about 50/1000 (2P < 0.00001)) and 6% v 8% in 16,000 other high risk patients (one year benefit about 20/1000 (2P < 0.00001)). Reductions in vascular events were about one quarter in each of these four main categories and were separately statistically significant in middle age and old age, in men and women, in hypertensive and normotensive patients, and in diabetic and nondiabetic patients. Taking all high risk patients together showed reductions of about one third in non-fatal myocardial infarction, about one third in non-fatal stroke, and about one third in vascular death (each 2P < 0.00001). There was no evidence that non-vascular deaths were increased, so in each of the four main high risk categories overall mortality was significantly reduced. The most widely tested antiplatelet regimen was "medium dose" (75-325 mg/day) aspirin. Doses throughout this range seemed similarly effective (although in an acute emergency it might be prudent to use an initial dose of 160-325 mg rather than about 75 mg). There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events. The optimal duration of treatment for patients with a past history of myocardial infarction, stroke, or transient ischaemic attack could not be determined directly because most trials lasted only one, two, or three years (average about two years). Nevertheless, there was significant (2P < 0.0001) further benefit between the end of year 1 and the end of year 3, suggesting that longer treatment might well be more effective. Among low risk recipients of "primary prevention" a significant reduction of one third in non-fatal myocardial infarction was, however, accompanied by a non-significant increase in stroke. Furthermore, the absolute reduction in vascular events was much smaller than for high risk patients despite a much longer treatment period (4.4% antiplatelet therapy v 4.8% control; five year

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Rainbow完成签到,获得积分10
刚刚
鶴0完成签到,获得积分10
1秒前
zhaonana完成签到 ,获得积分10
1秒前
乐乐的应助被HMMM采纳,获得10
1秒前
cocoli完成签到,获得积分10
1秒前
科研星完成签到,获得积分10
1秒前
HQ完成签到,获得积分10
1秒前
我和狂三贴贴完成签到,获得积分10
1秒前
优雅白柏完成签到,获得积分10
1秒前
一个酒窝完成签到 ,获得积分10
2秒前
2秒前
彭于晏的应助被寒冷的断秋采纳,获得10
2秒前
2秒前
3秒前
嘻嘻哈哈的应助被星光采纳,获得10
3秒前
娃哈哈完成签到,获得积分10
3秒前
刘秀平完成签到,获得积分10
3秒前
研友_841KWL完成签到,获得积分10
3秒前
华仔的应助被222采纳,获得10
4秒前
yuhuzhouye完成签到,获得积分10
4秒前
成林完成签到,获得积分10
4秒前
4秒前
乐观的蜜蜂完成签到,获得积分10
4秒前
kwangil完成签到,获得积分10
4秒前
4秒前
4秒前
张羡光完成签到,获得积分10
5秒前
老迟到的翠容完成签到,获得积分10
5秒前
3Q发布了新的文献求助10
5秒前
小二郎的应助被cyn采纳,获得10
5秒前
yippee完成签到,获得积分10
6秒前
HTT完成签到,获得积分10
6秒前
6秒前
充电宝的应助被attilio采纳,获得10
6秒前
6秒前
zonker完成签到,获得积分10
6秒前
淡淡向卉完成签到,获得积分10
6秒前
落九川完成签到,获得积分10
7秒前
大罗完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152442
求助须知:如何正确求助?哪些是违规求助? 9549069
关于积分的说明 21690841
捐赠科研通 7740658
什么是DOI,文献DOI怎么找? 3425157
关于科研通互助平台的介绍 2550382
邀请新用户注册赠送积分活动 2468710